# US 11,078,154 B2 · Compositions and methods for the treatment of irritable bowel syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,154 B2
- Document ID: US11078154B2
- Status: Granted
- Kind: B2
- Application number: 16/323,069
- Filed: 2017-04-19
- Published: 2019-06-13
- Granted: 2021-08-03
- Earliest claimed: 2016-08-11
- Assignees: Cellix Bio Private Limited
- Applicants: Cellix Bio Private Limited
- Inventors: Mahesh Kandula
- Web page: https://patentgrep.com/patent/US11078154B2

## CPC

- C07C 233/55: having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 15/00: Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
- C07C 229/60: with amino and carboxyl groups bound in meta- or para- positions
- C07C 229/14: to carbon atoms of carbon skeletons containing rings
- C07D 207/12: Oxygen or sulfur atoms
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

## Claims

### Claim 1

A compound of Formula I:
or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, or stereoisomers thereof;
wherein,
R1, R3, R5 each independently represents NULL,
R2, R4, R5 each independently represents

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of:
and